All Articles

In a strategic pivot, Skye Bioscience acquires Redx Pharma, creating Fibrx Therapeutics—a new Nasdaq-listed player armed with $125M and a bold plan.

With assets soaring 290% and revenue nearly doubling, PMGC Holdings' pivot to strategic acquisitions in aerospace and tech is paying off spectacularly.

How the Royal Canadian Mint's diversified model, blending global coin contracts with savvy metals trading, is delivering resilience and profit in a volatile Q2.

Reading International posts record post-pandemic profits, fueled by a stellar film slate. But beneath the surface, a surge in short-term debt reveals a high-stakes balancing act.

Shedding its IT baggage, Vaso Corp's Q2 results reveal a focused, profitable healthcare strategy. Is this the new blueprint for MedTech success?

The Detroit Lions' new VR deal isn't just about cool tech; it's a bold play to rewrite the rules of fan access and sports media rights forever.

New preclinical data shows NurExone's ExoPTEN protects vital nerve coatings, providing a biological basis for functional recovery in spinal cord injury models.

Beyond a simple donation, Yili's 150,000-ice cream giveaway in Thailand reveals a masterclass in using localized CSR to build brand loyalty and outmaneuver rivals.

How Madison Global’s top client-voted ranking reveals a winning formula blending high-tech platforms with high-touch service, setting a new standard.

Diodes Inc. secures a massive, interest-free war chest. While markets flinched at the news, the move reveals a calculated strategy for acquisitions and growth.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

A federal plan revives a post-war strategy with pre-approved home designs to speed up construction. But will this blueprint for affordability work in practice?

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

A new line of Brinks lock boxes isn't just about security; it's a strategic response to the shared economy's demand for trusted, flexible access.

As Evaxion prepares its Q2 update, investors watch to see if its AI-Immunology™ platform can deliver the financial and clinical results for long-term value.

Indiana Center for Recovery's sixth consecutive #1 ranking offers a playbook for quality care, but what does 'best' truly mean amid a public health crisis?

PMV Pharma's rezatapopt shows remarkable results for a tough cancer by reactivating a key defense. A deep dive into the science, finances, and patient hope.

AI now handles medical coding for New Jersey's independent doctors, boosting revenue and freeing them to focus on what matters: their patients.

Enterprises are pouring billions into AI, yet only 6% see a meaningful return. The problem isn't the model—it's the integration. Here's how to fix it.

Fannin Partners secures key grants to advance its Raptamer therapy for a rare pediatric cancer, highlighting a funding model vital for high-risk innovation.